Compare INSM & CHD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | CHD |
|---|---|---|
| Founded | 1988 | 1846 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0B | 23.4B |
| IPO Year | 2000 | 2014 |
| Metric | INSM | CHD |
|---|---|---|
| Price | $108.13 | $97.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 24 | 17 |
| Target Price | ★ $201.17 | $102.18 |
| AVG Volume (30 Days) | ★ 3.6M | 1.7M |
| Earning Date | 05-07-2026 | 05-01-2026 |
| Dividend Yield | N/A | ★ 1.28% |
| EPS Growth | N/A | ★ 27.43 |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $6,203,200,000.00 |
| Revenue This Year | $182.31 | $0.25 |
| Revenue Next Year | $65.19 | $3.65 |
| P/E Ratio | ★ N/A | $108.54 |
| Revenue Growth | N/A | ★ 1.57 |
| 52 Week Low | $90.39 | $81.33 |
| 52 Week High | $212.75 | $106.04 |
| Indicator | INSM | CHD |
|---|---|---|
| Relative Strength Index (RSI) | 49.73 | 52.24 |
| Support Level | $98.90 | $91.85 |
| Resistance Level | $119.54 | $100.48 |
| Average True Range (ATR) | 4.50 | 2.11 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 32.44 | 53.39 |
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Church & Dwight is the leading global producer of baking soda. Its portfolio extends beyond its legacy category to include laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its brands also include Batiste, OxiClean, Vitafusion, Hero, and TheraBreath, which, together with Arm & Hammer, account for around 70% of its annual sales and profits. Most recently, the firm added Touchland and its hand sanitizer business to its fold. Even as it works to expand its product reach, Church & Dwight still derives around 80% of its sales from its home market in the US.